-
1 month ago | 
nature.com | Oren Pasvolsky |Lei Feng |James Davis |Aimaz Afrough |Mariola Vazquez-Martinez |Utkarsh Goel | +22 more
AbstractTeclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants (n = 24) were ≥75 years old. In this multicenter retrospective study, we report real-world outcomes of a large cohort of older RRMM patients treated with teclistamab.
-
Mar 3, 2025 | 
nature.com | James Davis |Mikhaila Rice |Kelley Julian |Charlotte Wagner |Shebli Atrash |Jack Khouri | +1 more
TO THE EDITOR:Cytokine release syndrome (CRS) is a systemic inflammatory response triggered by the activation of T-cells and is commonly seen in patients receiving immune effector cell therapies such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies (BsAbs) which target varying tumor antigens such as CD19, CD20, B-cell maturation antigen (BCMA), or GPRC5D depending on the type of malignancy.
-
Dec 4, 2024 | 
nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Nov 28, 2024 | 
onlinelibrary.wiley.com | Ludovic Saba |Raymond L. Comenzo |Jack Khouri |Faiz Anwer
Conflicts of Interest The authors declare no conflicts of interest. Supporting Information Filename Description ejh14347-sup-0001-SupinfoS1.docxWord 2007 document , 64.5 KB Data S1. Supporting Information. ejh14347-sup-0002-SupinfoS2.docxWord 2007 document , 19.1 KB Data S2. Supporting Information. References 1 and , “How I Treat AL Amyloidosis,” Blood 139, no. 19 (2022): 2918–2930.
-
Jul 14, 2024 | 
onlinelibrary.wiley.com | Jack Khouri
POEMS syndrome (POEMS) is a rare, systemic plasma cell disorder with various clinical and laboratory manifestations rendering it an elusive diagnosis.1, 2 Peripheral neuropathy is a dominant symptom of POEMS, is typically demyelinating, ascending and sensory at the outset. Motor symptoms tend to develop with time leading to muscle atrophy and significant debility.
-
Apr 12, 2024 | 
onlinelibrary.wiley.com | Ludovic Saba |Chieh-Lin Fu |Jack Khouri |Beth Faiman
Multiple myeloma (MM) is a complex hematological malignancy characterized by malignant plasma cell proliferation usually within the bone marrow.1 Patients diagnosed with MM face multiple challenges, including understanding the intricacies of their condition, available treatment modalities, side effects, supportive care, and the consequent prognostic implications.
-
Feb 29, 2024 | 
mdpi.com | Omar Nadeem |Sikander Ailawadhi |Jack Khouri |Louis Williams
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
-
Dec 6, 2023 | 
frontiersin.org | Patient-Centered Research |Jean Cheikh |Catarina Geraldes |Jack Khouri
1 IntroductionThe incidence of multiple myeloma (MM) is highly variable across countries but has increased uniformly since 1990 (1, 2). This hematologic cancer disproportionately affects older patients (median age of diagnosis >70 years) in whom the burden of adverse events and decline in health-related quality of life (HRQoL) can be particularly high (3, 4).
-
Nov 17, 2023 | 
cancernetwork.com | Andrew Kin |Jeffrey Zonder |Craig Cole |Jay Yang |Charles A. Schiffer |Jack Khouri | +3 more
Transcript:Jack Khouri, MD: So, Greg, we seem like a big fan of this. Craig Cole, MD: I didn’t want to tell you. But the patients that I had on [the trial] are what make me a fan. The patients I had when we had to discontinue in November had to stop therapy and remain in very good, or even CRs [complete responses] for months and months. I think the longest one is a patient I still have from November when I discontinued, and she’s still in a CR.
